The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases

 Nami McCarty, Ph.D.

Nami McCarty, Ph.D.

Assistant Professor, Center for Stem Cell and Regenerative Medicine 

Nami.McCarty@uth.tmc.edu

713-500-2495

As a postdoctoral fellow and instructor in Dr. Cantor's laboratory at the Dana-Farber Cancer Institute, Dr. McCarty pursued projects that have led directly to several significant findings. She used SAGE to identify transcripts expressed in the two major thymocyte lineages; this includes 27 highly differentially expressed genes in these two subsets. Additionally, she had developed a novel application involving lentivirus-encoded shRNA constructs to selectively knock down gene expression in mice. This technique has enabled investigation of the functions of the various gene products identified by SAGE. Lastly, she combined these approaches to identify and characterize MINK as a critical signaling molecule necessary for T cell development and differentiation.

In 2006, Dr. McCarty received a Career Developmental Award from the National Institutes of Health-NIAID and subsequently joined the Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center at Houston as an Assistant Professor. She received an outstanding young investigator award in 2007. She was awarded several extramural and intramural grants since she joined IMM, including an award from The Concern Foundation, a Research Scholar Award from American Cancer Society (ACS).

The main research subjects of her lab are the identification and characterization of stem cell populations in mantle cell lymphoma (MCL) and multiple myeloma (MM).  MCL is highly refractory to standard therapy and displays the worst survival rate among Non-Hodgkin's Lymphoma. Dr. McCarty lab has reported stem-cell like populations in human mantle cell lymphoma. The stem-like populations could contribute to tumor recurrence after drug treatment. These findings will facilitate the development of new preclinical models that will serve as the groundwork for the design of novel therapeutic strategies to treat or prevent the pathogenesis of MCL and MM in humans.

Cho, N., Cheuh, P-J., Kim, C.P., Caldwell, D., Morre, D.M., Morre, D. J. (2002) A monoclonal

antibody to a cancer-specific and drug-responsive hydroquinone oxidase from a sera of cancer patients. Cancer. Immunol. Immunother. 51:121-129.

Panoutsakopoulou, V., Huster, K.M., McCarty, N., Feinberg, E., Wang, R., Wucherpfennig, K.W., Cantor, H. (2004) Suppression of autoimmune disease after vaccination with autoreactive T cells that expresses Qa-1 peptide complexes. J. Clin. Invest. 113:1218-1224.

Paust, S., Lu, L., McCarty, N., Cantor, H. (2004) Molecular target of regulatory T cells: engagement of CD80/86 on effector T cells inhibits expansion and prevents autoimmune disease. Pro. Natl. Acad. Sci. 101:10398-10403.

McCarty, N., Shinohara, M.L., Lu, L., Cantor, H. (2004) Detailed analysis of gene expression during development of T cell lineages in the thymus. Proc. Natl. Acad. Sci. 101:9339-9344.

Cho, N., Morre, J.D. (2009) Early developmental expression of a normally tumor-associated and drug-inhibited cell surface located NADH oxidase (ENOX2) in non-cancer cells. Cancer. Immunol. Immunother. 58:547-552.

McCarty, N., Paust, S., Ikizawa, K., Dan, I., Li, X., Cantor, H. (2005) Signaling by MINK

plays an essential role in negative selection of autoreactive thymocytes. Nature Immunology 6:65-72. 

Arias. D.A*., McCarty, N*., Lu, L., Maldonado, R.A., Shinohara, M.L., Cantor, H. (2010) Unexpected role of clathrin adaptor AP-1 in MHC-dependent positive selection of T cells.

Proc. Natl. Acad. Sci. 107:2556-2561. * Co-first author   

Zheng, C., Ayala, P., Wang, M., Fayad, L., Katz, R., Romaguera, J.E., Caraway, N., Neelapu, S.S., Kwak, L., Simmons, P.J., McCarty, N.* (2010) Identification of clonogenic Mantle Cell Lymphoma initiating cells. Stem Cell Research 5:212-225.           

Jung, H-J., Zheng, C., McCarty, N*. (2011) Stem-like tumor cells confer drug resistant properties to Mantle Cell Lymphoma. Leukemia and Lymphoma. 52:1066-1079. 

Jung, H-J., Zheng, C., McCarty, N*. (2011) Drug resistant stem-like tumor cells. Clinical Lymphoma, Myeloma and Leukemia. 11:131.

Jung, H-J., Zheng, C., Fayad, L., Wang, M., Romaguera, J., Kwak, L.W., and McCarty, N*. (2012) Bortezomib-resistant nuclear factor kappa B expression in stem like cells in mantle cell lymphoma (MCL). Experimental Hematology. Accepted. Epub ahead of print. PMID: 22024108

Jung, H-J., Zheng, C., Wang, M., Fayad, L., Romaguera, J., Kwak, L.W., and McCarty, N*. (2012) Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. Blood. Accepted.